



PRESS RELEASE

Alpha IVF receives greenlight to list on ACE market of Bursa Malaysia

- *Fertility care specialist secures the approval of Bursa Malaysia Securities Berhad, set for next stage of expansion*

Kuala Lumpur, Malaysia, 15 January 2024 - Fertility care specialist Alpha IVF Group Berhad (“Alpha IVF” or “Company” or “阿儿法国际辅助生殖集团”) and its subsidiaries (collectively referred to as “the Group”) has received the approval of Bursa Malaysia Securities Berhad (“Bursa Securities”) to list on the ACE Market of Bursa Securities.

Alpha IVF is a fertility care specialist currently operating in Malaysia and Singapore, providing assisted reproductive services (“ARS”) with a primary focus on in-vitro fertilisation (“IVF”). The Group presently operates two specialist centres in Malaysia, namely Alpha International Women’s Specialists Sdn. Bhd. (“Alpha KL”) in Selangor and Genesis Specialists Sdn. Bhd. (“Genesis”) in Penang, and one specialist centre in Singapore, Alpha International Women’s Specialists (Singapore) Pte. Ltd. (“Alpha Singapore”).

In addition to catering to the healthcare needs of local patients, the Group’s Malaysian operations have become a hub for foreign patients from Indonesia, China, Singapore, Australia, and other countries. The Group has innovated numerous treatments leading to improved pregnancy rates since its inception in 2011, and is actively involved in using artificial intelligence (“AI”) to enhance the IVF process.

“Our commitment to empowering families and advancing reproductive health care has brought us to this milestone. The approval to list on ACE Market not only marks a significant step in our next growth stage but also reinforces our dedication to making the dreams of parenthood a reality.

Over the years, Alpha IVF has become a trusted name in the region in helping couples on their journey to parenthood. We have consistently delivered high success rates in the field of ARS, demonstrated by our strong track record and clinical experiences.

The growing need for ARS poses an opportune moment for our expansion, enabling us to strategically capitalize on emerging opportunities, and extending to benefit even more patients with our high pregnancy rates. The floatation exercise and Bursa Securities’ approval bring us closer to achieving our mission of becoming a leading fertility care specialist in the region.”

Dato’ Dr Colin Lee Soon Soo
Group Managing Director, Alpha IVF Group Berhad



Besides IVF, the Group also provides other assisted reproductive procedures including intracytoplasmic sperm injection, intrauterine insemination, various diagnostics, testing and screening procedures, as well as cryopreservation of eggs, sperms and embryos.

Barring unforeseen circumstances, Alpha IVF targets to be listed in the first quarter of 2024. AmInvestment Bank Berhad is the principal adviser, sponsor, lead placement agent, joint placement agent, and sole underwriter for the Group's initial public offering exercise.

-- End --

Issued for and on behalf of ALPHA IVF GROUP BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd.
For media enquiries, please contact:

Ms. Azja Delana

azja@aquilas.com.my

T: 03-2711 1391